LT3723858T - Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę - Google Patents
Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinęInfo
- Publication number
- LT3723858T LT3723858T LTEPPCT/EP2019/086808T LTEP2019086808T LT3723858T LT 3723858 T LT3723858 T LT 3723858T LT EP2019086808 T LTEP2019086808 T LT EP2019086808T LT 3723858 T LT3723858 T LT 3723858T
- Authority
- LT
- Lithuania
- Prior art keywords
- fixaxfx
- light chain
- bispecific antibody
- common light
- common
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3723858T true LT3723858T (lt) | 2022-02-10 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2019/086808T LT3723858T (lt) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220064327A1 (lt) |
| EP (2) | EP3723858B1 (lt) |
| JP (1) | JP7530362B2 (lt) |
| KR (1) | KR20210118085A (lt) |
| CN (1) | CN113453757B (lt) |
| BR (1) | BR112021012065A2 (lt) |
| CA (1) | CA3123177A1 (lt) |
| DK (1) | DK3723858T3 (lt) |
| ES (1) | ES2901683T3 (lt) |
| HR (1) | HRP20220088T1 (lt) |
| HU (1) | HUE057634T2 (lt) |
| LT (1) | LT3723858T (lt) |
| PL (1) | PL3723858T3 (lt) |
| PT (1) | PT3723858T (lt) |
| RS (1) | RS62848B1 (lt) |
| SI (1) | SI3723858T1 (lt) |
| TW (1) | TWI772724B (lt) |
| WO (1) | WO2020128049A1 (lt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| TWI772724B (zh) * | 2018-12-21 | 2022-08-01 | 英商克馬伯有限公司 | 具有共同輕鏈的FIXaxFX雙專一性抗體 |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| EP4473008A2 (en) * | 2022-01-31 | 2024-12-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treating factor ix deficiency |
| US12098400B2 (en) | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP1693448A4 (en) | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
| EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US20100003254A1 (en) | 2005-04-08 | 2010-01-07 | Chugai Seiyaku Kabushiki Kaisha | Antibody Substituting for Function of Blood Coagulation Factor VIII |
| CA2614076A1 (en) | 2005-07-05 | 2007-01-11 | Glaxo Group Limited | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| CA2650131A1 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| RU2522002C2 (ru) | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
| US20130018174A1 (en) * | 2009-12-25 | 2013-01-17 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| EA035344B1 (ru) | 2012-04-20 | 2020-05-29 | Мерюс Н.В. | Способ получения двух антител из одной клетки-хозяина |
| EP2906599B1 (en) | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| EP2992010B1 (en) * | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| JP2017500372A (ja) | 2013-11-04 | 2017-01-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 出血または凝固性低下と関係する容態の治療療法または予防療法 |
| JP6706578B2 (ja) | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリン及びその使用 |
| TW201625299A (zh) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| US20180179274A1 (en) * | 2015-06-26 | 2018-06-28 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| US10618952B2 (en) | 2015-10-30 | 2020-04-14 | Medimmune Limited | Prevention of N-terminal truncation in IgG light chains |
| EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| IL260937B2 (en) | 2016-02-06 | 2024-07-01 | Epimab Biotherapeutics Inc | FABS antibodies one by one and their uses |
| CA3024485A1 (en) | 2016-05-16 | 2017-11-23 | Baxalta Incorporated | Anti-factor ix padua antibodies |
| CA3027018A1 (en) * | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| MA46200A (fr) | 2016-09-06 | 2019-07-17 | Chugai Pharmaceutical Co Ltd | Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé |
| CA3044574A1 (en) * | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| CA3051639A1 (en) | 2017-02-01 | 2018-08-09 | Novo Nordisk A/S | Procoagulant antibodies |
| CN110494163A (zh) | 2017-02-06 | 2019-11-22 | 应用干细胞有限公司 | 凝血因子viii模拟蛋白及其用途 |
| US11447564B2 (en) * | 2017-04-26 | 2022-09-20 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| WO2018209265A1 (en) | 2017-05-11 | 2018-11-15 | Atreca, Inc. | Anti-malarial antibodies that bind circumsporozoite protein |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US10759870B2 (en) | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
| MA50893A (fr) | 2017-11-15 | 2020-09-23 | Novo Nordisk As | Liants de facteur x renforçant l'activation fx |
| TWI772724B (zh) | 2018-12-21 | 2022-08-01 | 英商克馬伯有限公司 | 具有共同輕鏈的FIXaxFX雙專一性抗體 |
-
2019
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en active Pending
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en unknown
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko unknown
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021012065A2 (pt) | 2021-12-07 |
| EP3723858A1 (en) | 2020-10-21 |
| RS62848B1 (sr) | 2022-02-28 |
| DK3723858T3 (da) | 2022-01-24 |
| CN113453757A (zh) | 2021-09-28 |
| US11976135B2 (en) | 2024-05-07 |
| EP4015538A1 (en) | 2022-06-22 |
| SI3723858T1 (sl) | 2022-04-29 |
| JP2022515770A (ja) | 2022-02-22 |
| PL3723858T3 (pl) | 2022-03-07 |
| WO2020128049A1 (en) | 2020-06-25 |
| EP3723858B1 (en) | 2021-10-27 |
| HRP20220088T1 (hr) | 2022-04-15 |
| HUE057634T2 (hu) | 2022-05-28 |
| CA3123177A1 (en) | 2020-06-25 |
| TWI772724B (zh) | 2022-08-01 |
| ES2901683T3 (es) | 2022-03-23 |
| PT3723858T (pt) | 2022-02-02 |
| CN113453757B (zh) | 2024-06-28 |
| US20220064327A1 (en) | 2022-03-03 |
| US20210101997A1 (en) | 2021-04-08 |
| KR20210118085A (ko) | 2021-09-29 |
| JP7530362B2 (ja) | 2024-08-07 |
| US20200199250A1 (en) | 2020-06-25 |
| US10815308B2 (en) | 2020-10-27 |
| TW202039584A (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| EP3243840B8 (en) | Bispecific antibody or antibody mixture with common light chains | |
| LT3723858T (lt) | Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| SG11202004172UA (en) | Il2rbeta/common gamma chain antibodies | |
| EP3825404A4 (en) | Anti-gpc3 single-chain antibody-containing car | |
| ZA202004908B (en) | Bispecific antibody | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| CA185679S (en) | Light | |
| HK1247941A1 (zh) | 抗替代性輕鏈抗體 | |
| CA187452S (en) | Light | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| IL286757A (en) | Antibodies in specific | |
| CA187451S (en) | Light | |
| HK1258306A1 (zh) | 具有共同輕鏈的轉基因兔 | |
| CA187450S (en) | Light | |
| IL286918A (en) | Bispecific antibody | |
| IL290050A (en) | Bispecific antibody | |
| ZA202206008B (en) | Bispecific anti-ccl2 antibodies | |
| GB201820977D0 (en) | Fixaxfx bispecific antibody with commomn light chain | |
| GB201908190D0 (en) | Fixaxfx bispecific antibody with common light chain | |
| GB201906816D0 (en) | FIXaxFX bispecific antibody with common light chain | |
| CA187087S (en) | Backpack with light | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| PL3594565T3 (pl) | Światło samochodowe |